IBJNews

Lilly plans more investment in two-in-one drugs

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s newest plan for breakthrough biotech drugs relies on an old business strategy: package deals.

The Indianapolis-based drugmaker on Tuesday plans to announce a new multimillion-dollar investment to develop drugs that act like two medicines in one.

Lilly did not disclose the amount of money it is spending on the initiative. The company is unveiling the plans at a convention in Washington, D.C.

The idea is to engineer the DNA of proteins so that one molecule can hit two or more targets in a patient’s cells. Lilly says it already has used protein engineering to develop several of these multi-specific therapeutics. Now it wants to move them into human testing.

Lilly hopes the new drugs also could be engineered to produce fewer side effects to patients.

To put the effort into action, Lilly intends to hire as many as 40 workers between its biotechnology center in Indianapolis and its molecular engineering unit in San Diego. About 35-40 employees now work on the two-in-one drug initiative.

Also, scientists will do a review of Lilly’s library of proteins developed in previous decades of research—most of which were never brought to market—to see if any could be good candidates to be engineered into a multi-specific drug.

Lilly is aiming at some high-dollar diseases, mainly diabetes and cancer, where patients often have to take multiple medications to treat their disease.

“With our extensive biologics experience, we can now engineer new therapies where one medicine essentially provides the benefit of two. This could produce real benefits for patients, health care professionals and payors,” said Tom Bumol, Lilly’s vice president of biotechnology discovery research.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT